Bivalirudin
- Generic Name
- Bivalirudin
- Brand Names
- Angiomax
- Drug Type
- Small Molecule
- Chemical Formula
- C98H138N24O33
- CAS Number
- 128270-60-0
- Unique Ingredient Identifier
- TN9BEX005G
- Background
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activat...
- Indication
For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
- Associated Conditions
- Thrombosis
- Associated Therapies
- -
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
- Conditions
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Xiaotong Hou
- Target Recruit Count
- 154
- Registration Number
- NCT06275555
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, Beijing, China
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05984537
- Locations
- 🇨🇳
Peking university first hospital, Beijing, Beijing, China
BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Sydney Local Health District
- Target Recruit Count
- 80
- Registration Number
- NCT05959252
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- University Magna Graecia
- Target Recruit Count
- 58
- Registration Number
- NCT05334654
- Locations
- 🇮🇹
AOU Mater Domini, Catanzaro, Italy
Safety and Efficacy of Bivalirudin During Short-term Intervention of Non-infarction Related Artery After PPCI of STEMI
- Conditions
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2022-05-02
- Target Recruit Count
- 100
- Registration Number
- NCT04475835
- Locations
- 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion
- Conditions
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04195997
- Locations
- 🇨🇳
Zhongshan Hopital of Fudan University, Shanghai, Shanghai, China
Bivalirudin in Late PCI for Oatients With STEMI
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2019-12-10
- Target Recruit Count
- 1200
- Registration Number
- NCT04185077
Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2019-08-06
- Target Recruit Count
- 240
- Registration Number
- NCT04046029
- Locations
- 🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian, China
Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Legacy Health System
- Target Recruit Count
- 34
- Registration Number
- NCT03965208
- Locations
- 🇺🇸
Legacy Health System, Portland, Oregon, United States
Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2019-03-20
- Target Recruit Count
- 240
- Registration Number
- NCT03882775
- Locations
- 🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.